Clinical Trial

Mission Therapeutics awarded $5.2m from The Michael J. Fox Foundation and Parkinson’s UK to advance potential disease-modifying treatment MTX325

Investment will support investigation of Mission's small molecule drug MTX325 in patients with early-stage Parkinson's diseaseMarks latest step in Mission's…

2 weeks ago

IRLAB’s Phase IIb Study of Pirepemat Can Proceed as Planned after Positive Opinion from External Safety Committee

GOTHENBURG, SWEDEN / ACCESSWIRE / July 2, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, July 2, 2024 - IRLAB Therapeutics…

2 weeks ago

Aptevo Therapeutics Announces Closing of $2.75 Million Offering

SEATTLE, WA / ACCESSWIRE / July 1, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing…

3 weeks ago

HistoIndex Charts New Course in Liver Disease Innovation: Announces Pivotal Changes to Scientific Advisory Board

Company to appoint Prof. Arun J. Sanyal as the new Chairman of HistoIndex's Scientific Advisory Board, bringing unparalleled expertise to…

3 weeks ago

Enzolytics, Inc. Enters Into Exclusive Worldwide License for Patented Immunotherapy Cancer Treatment

Update on Sagaliam Acquisition Corp. ALLEN, TX / ACCESSWIRE / July 1, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) ("enzolytics.com") (the…

3 weeks ago

US Equestrian Names Zomedica’s PulseVet System as the Official Shock Wave Therapy of US Equestrian Team Veterinarians

PulseVet® Shock Wave Device Supports Equine Athletes Ahead of Major International Team Events ANN ARBOR, MI / ACCESSWIRE / July…

3 weeks ago

GRI Bio to Present at the 8th Annual IPF Summit

LA JOLLA, CA, July 01, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a…

3 weeks ago

Prenetics Welcomes Kathyrn M. Henry and David Vanderveen to Board of Directors

Adding Decades of Public Company and Board Expertise as Prenetics Readies for Expansion into Consumer Health and WellnessLOS ANGELES, July…

3 weeks ago

Inside information: Orion and MSD Announce Mutual Exercise of Option Providing MSD Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer

ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION1 JULY 2024 at 15:15 EEST         Inside information: Orion and MSD Announce Mutual Exercise…

3 weeks ago